Treacy, Joanne
Morrato, Elaine H.
Horne, Robert
Wolf, Michael S.
Bakhai, Ameet
Wilson, Marie-Claire
Lightowler, Mark
Guerler, Sibel
Jokinen, Jeremy http://orcid.org/0000-0001-8484-5788
Funding for this research was provided by:
Bristol-Myers Squibb
Article History
Accepted: 7 March 2024
First Online: 9 April 2024
Declarations
:
: Axian Consulting has received consulting fees for supporting the work relating to this publication. No other funds, grants, or other type of support was received.
: At the time of writing, JT was an independent contractor with Bristol Myers Squib. JT received speaker engagements and honoraria with the Drug Safety Research Unit. The content is solely the responsibility of the author. EHM has received funding for consulting services on issues of drug safety from Eli Lilly, Health Care Service Corporation, Inc., i2o, Humana Inc., Ipsen, Molina Healthcare, Inc., Reata Pharmaceuticals, Syneos Health, and United Healthcare Services. The terms of this arrangement have been reviewed and approved by Loyola University Chicago in accordance with its policy on objectivity in research. EHM receives funding support from the National Center for Advancing Translational Science in the National Institutes of Health under award number 2UL1TR002389. The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health. RH is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC), North Thames at Bart's Health NHS Trust, and Asthma UK (AUKCAR). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. Over the last decade, there have been speaker engagements and honoraria with the following companies: AbbVie, Abbott, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, BMS, Biogen, Biomerieux Gilead Sciences, GlaxoSmithKline, Janssen, Merck Sharp Dohme, Merck, Novartis, Pfizer, Procter & Gamble, Roche, Sanofi, Shire Pharmaceuticals, TEVA, and UCB. RH is Founding Director of a UCL-Business company (Spoonful of Sugar Ltd), providing consultancy on treatment engagement and patient support programs to healthcare policy makers, providers, and the pharmaceutical industry. MSW consults/has provided consultation for BMS, Pfizer, Lundbeck, GlaxoSmithKline, and Sanofi Pharmaceuticals, and also Luto, UK on medication safety-related issues; he has also received grant support through his institution from Pfizer, Lundbeck, Merck, and Eli Lilly. These engagements have been reviewed and approved by Northwester University. AB is the founder of Amore Health Ltd and has equity in Salutare, receives honorarium from Amarin, Amgen, Astra Zeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Lilly, Napp, Novartis, Pfizer, and Roche for lecturing and scientific advice. M-CW is a full-time employee of Axian Consulting Ltd. Axian Consulting has received consulting fees for supporting the work relating to this publication. SG is a full-time employee of Bristol Myers Squibb. JJ is a full-time employee of Bristol Myers Squibb. ML is the founder of Phorix Limited and has received payments from Roche, Novartis, Vaderis, Merck, and Takeda for scientific and strategic advice.
: Not applicable.
: Not applicable.
: Code availability is not applicable to this article, as no datasets were generated or analyzed and no code was written as part of the work.
: This article does not include personal information about individuals, and therefore, consent for the publication of this information was not required.
: This article did not involve participation of human subjects, and therefore, consent to participate was not required.
: All authors contributed equally to the conception and writing of this manuscript. All authors read and approved the final manuscript.